STOCK TITAN

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced a proposed public offering of common stock and prefunded warrants to certain investors. The offering, managed by Piper Sandler, Guggenheim Securities, and Truist Securities, includes an option for underwriters to purchase additional shares. The offering is subject to market conditions and regulatory approvals.
Positive
  • None.
Negative
  • None.

The announcement by Praxis Precision Medicines of a proposed public offering, including both common stock and prefunded warrants, is a significant event that warrants an evaluation of its potential impact on the company's financial health and market valuation. This type of offering is often undertaken by companies seeking to raise capital to fund operations, research and development, or to pay off existing debts. In the case of Praxis, a clinical-stage biopharmaceutical company focused on CNS disorders, the infusion of funds could accelerate their research pipeline and potentially bring therapies to market more quickly.

However, investors should be aware of the dilutive effect of such offerings, where the introduction of additional shares could lead to a decrease in existing shareholders' equity. The market's reception to this news can vary; a positive response could indicate investor confidence in the company's future, while a negative reaction could reflect concerns over dilution or the company's need for additional capital. The involvement of established financial institutions as book-runners and managers may lend credibility to the offering, but the final terms disclosed in the final prospectus supplement will be critical in assessing the offering's attractiveness.

From a market perspective, Praxis' decision to engage in a public offering is a strategic move that can be influenced by several external factors, such as market conditions and investor sentiment towards the biopharmaceutical sector. The timing of the offering, in relation to market performance and sector-specific trends, can significantly affect the success of the capital raise. For instance, a bullish market or positive news within the CNS therapeutic area could enhance the offering's success.

Additionally, the 30-day option for underwriters to purchase additional shares up to 15% of the offering provides a buffer that could help stabilize the stock price post-offering. It is also indicative of the underwriters' confidence in the offering's potential success. The market will closely monitor the uptake of this option as an indicator of institutional confidence in Praxis' growth trajectory and the underlying value of its research portfolio.

The realm of central nervous system disorders presents a challenging yet highly rewarding space for biopharmaceutical companies like Praxis Precision Medicines. The company's focus on translating genetic insights into therapies is a cutting-edge approach that aligns with current industry trends towards personalized medicine. The funds raised through this offering could significantly bolster Praxis' position within the biotech industry, allowing for the advancement of their pipeline products through clinical trials, which is a critical step towards FDA approval and commercialization.

Investors should consider the high-risk, high-reward nature of the biotech sector, where the development timeline can be protracted and uncertain. The success of Praxis' therapies in clinical trials will be a major determinant of the company's future revenue and growth potential. Therefore, the proposed offering could be seen as an investment into the company's long-term strategic development rather than immediate financial gain.

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. In addition, Praxis intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount up to 15% of the shares of common stock (or prefunded warrants in lieu thereof) sold in the offering at the public offering price, less the underwriting discount and commission.

Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Needham & Company are acting as co-lead managers for the offering. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed.

The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed by Praxis with the Securities and Exchange Commission (SEC) on March 5, 2024 and declared effective by the SEC on March 12, 2024. The proposed offering will be made only by means of a preliminary prospectus supplement and the accompanying base prospectus. A copy of the preliminary prospectus relating to the offering, when available, may be obtained from: Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, GA 30326, by telephone at (800) 685-4786, or by email at TruistSecurities.prospectus@Truist.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including, without limitation, statements regarding the completion, timing and size of the proposed public offering and Praxis’ expectations with respect to granting the underwriters a 30-day option to purchase additional shares, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation, risks related to market conditions and other risks described in Praxis’ Annual Report on Form 10-K for the year ended December 31, 2023 and other filings made with the SEC. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.


FAQ

What did Praxis Precision Medicines, Inc. (PRAX) announce?

Praxis Precision Medicines, Inc. announced a proposed public offering of its common stock and prefunded warrants to certain investors.

Who are the joint book-running managers for the offering?

Piper Sandler, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering.

What type of securities will be offered in the proposed offering?

Common stock and prefunded warrants to purchase shares of common stock will be offered by Praxis in the proposed offering.

When was the shelf registration statement filed with the SEC?

The shelf registration statement on Form S-3 was filed by Praxis with the Securities and Exchange Commission (SEC) on March 5, 2024 and declared effective on March 12, 2024.

Where can interested parties obtain a copy of the preliminary prospectus?

Interested parties can obtain a copy of the preliminary prospectus from Piper Sandler & Co., Guggenheim Securities, or Truist Securities.

Is the offering subject to market conditions?

Yes, the offering is subject to market and other customary closing conditions.

What will be disclosed in the final prospectus supplement?

The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Praxis Precision Medicines, Inc.

NASDAQ:PRAX

PRAX Rankings

PRAX Latest News

PRAX Stock Data

765.92M
13.21M
0.17%
48.92%
3.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON

About PRAX

praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res